Novartis


Novartis   link
Ort: Basel
Hauptporte - MainGate, Fabrikstrasse 2, 4056 Basel

Kategorie: Pharmakologie
Verbunden:

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.

logo

Pharmakologie - Gesundheit - 24.11
Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in terms of assets and geographies Key growth drivers now contributing to 48% of Innovative Medicines sales ; upcoming launches expected to lay the foundation for future sales expansion Advancing leading p
Pharmakologie - Gesundheit - 19.11

Pivotal ASCEMBL study of novel, investigational STAMP inhibitor asciminib (ABL001) vs.

Pharmakologie - Gesundheit - 19.11

Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel -L for treatment of acute respiratory distress syndrome (ARDS) and other indications Addition of remestemcel -L could expand Novartis respiratory portfolio by adding potential first-in-class ARDS therapy using innovative cell-bas

Pharmakologie - Gesundheit - 13.11

Initial findings on patient characteristics and event likelihood provide insights related to Beovu use in wet AMD 1,2 -   Follows establishment of multi-disciplinary expert coalition and Novartis commitment to sharing data and findings with ophthalmology community -   Despite existing therapies, significant unmet need still exists for wet AMD pa

Pharmakologie - Gesundheit - 5.11

Significant reduction of synovitis (joint lining inflammation) was demonstrated with Cosentyx   at Week 12  vs.

Pharmakologie - Gesundheit - 30.10

Foundation for Biomedical Research and Innovation (FBRI) in Kobe, Japan becomes first CAR-T cell therapy commercial manufacturing site in Asia -   Novartis global CAR-T manufacturing footprint now spans four continents, bringing Kymriah closer to patients and healthcare professionals around the world -   Prestigious FBRI is recognized for its wo

Umwelt - 19.11

Five virtual power purchase agreements (VPPAs) with three developers expected to add more than 275 megawatts of clean power to the electrical grid Projects expected to address Novartis greenhouse gas emissions across its European operations, equivalent to removing approximately 1 13 000 passenger vehicles from the road annually 1 Agreements mark

Pharmakologie - Gesundheit - 13.11

  Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories 1,2 Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences 1 ,2 with two

Gesundheit - Pharmakologie - 6.11

The Phase III trial investigating canakinumab plus standard of care (SoC) did not meet its primary endpoint of a greater chance of patient survival without the need for invasive mechanical ventilation , or its key secondary endpoint of reduced COVID-19 mortality, compared with SoC 1 Ilaris (canakinumab) r emains an effective treatment option for its approved indications , with a well-characterized safety profile 2 ,3 .

Pharmakologie - Gesundheit - 2.11

The first randomized, double blind, head-to-head study of Aimovig (erenumab ) against topiramate in patients with episodic and chronic migraine (HER-MES) achieved superiority in its primary and secondary endpoints Aimovig showed superior tolerability and efficacy against topiramate and provided a significant reduction in monthly migraine days (M

Pharmakologie - Gesundheit - 30.10

Adakveo is the first targeted sickle cell disease therapy for prevention of recurrent vaso-occlusive crises (VOCs) available for use in Europe Clinical data showed that use of Adakveo led to a significant reduction in the rate of VOCs and to fewer days spent in hospital VOCs disrupt patients' lives physically, socially, and emotionally - and can